Sector | Other | Compare with Sector peers |
Industry | Business Support | Compare with Industry peers |
Website | http://www.vantabio.com | |
Market Cap | 38.83 Cr. | |
Enterprise Value(EV) | 63.43 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | -10.27 | Trailing Twelve Months Ending 2023-03 |
Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-03 |
Industry PE | 63.04 | Trailing Twelve Months Ending 2023-03 |
Book Value / Share | 27.75 | Trailing Twelve Months Ending 2023-03 |
Price to Book Value | 2.22 | Calculated using Price: 61.51 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 0.63 Cr. | 6,312,000 Shares |
FaceValue | 10 | |
About Vanta Bioscience Ltd. | ||
The company is a preclinical contract research organization, offering a host of preclinical safety assessment services for clientele from Pharmaceutical, Medical Devices, Nutraceuticals, Feed Additive, Biotech, Agrochemicals, Cosmetics, and Chemical industries. In addition they also provide risk assessment services for evaluating the safety of the Active Pharmaceutical Ingredients (API), excipients, extractable and leachables including pharmaceutical impurities resulting due to manufacturing process or due to degradation of the product. VBS also provides expert services for determination of health based exposure limits (e.g. permitted daily exposure (PDE) or allowable daily exposure (ADE) including occupational exposure limits (OEL) for pharmaceutical manufacturers. Their services include toxicology, batch release tests, biocompatibility studies, chemical safety, and diet formulation. |
1 Day |
|
|
1 Week |
|
-3.07% |
1 Month |
|
-13.20% |
3 Month |
|
+6.03% |
6 Month |
|
+47.13% |
1 Year |
|
+17.70% |
2 Year |
|
-45.11% |
5 Year |
|
-67.63% |
10 Year |
|
5 years | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 3.14 | 4.43 | 1.89 | 0.56 | -50.31 | |
Return on Capital Employed (%) | 7.87 | 8.62 | 5.42 | 4 | -6.1 | |
Return on Assets (%) | 1.78 | 2.31 | 0.76 | 0.18 | -12.57 |
Particulars | 6 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 22 | 23 | 24 | 24 | 18 | 17 | |
Non Curr. Liab. | 13 | 14 | 29 | 38 | 48 | 47 | |
Curr. Liab. | 3 | 10 | 15 | 14 | 18 | 18 | |
Minority Int. | 1 | 1 | 2 | 5 | 1 | 2 | |
Equity & Liab. | 39 | 49 | 70 | 81 | 85 | 85 | |
Non Curr. Assets | 22 | 29 | 50 | 67 | 69 | 69 | |
Curr. Assets | 17 | 20 | 20 | 15 | 15 | 15 | |
Misc. Exp. not W/O | |||||||
Total Assets | 39 | 49 | 70 | 81 | 85 | 85 |
Particulars | 5 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Net Sales | 12 | 14 | 10 | 10 | 6 | |
Other Income | 0 | 0 | 0 | 0 | 1 | |
Total Income | 12 | 14 | 10 | 10 | 7 | |
Total Expenditure | -9 | -9 | -6 | -6 | -9 | |
PBIDT | 4 | 4 | 4 | 4 | -2 | |
Interest | -2 | -2 | -2 | -2 | -6 | |
Depreciation | -1 | -1 | -1 | -1 | -3 | |
Taxation | 0 | 0 | 0 | 0 | 0 | |
Exceptional Items | ||||||
PAT | 1 | 1 | 0 | 0 | -10 | |
Minority Interest | 0 | 0 | 4 | |||
Share Associate | ||||||
Other Related Items | ||||||
Consolidated Net Profit | 1 | 1 | 0 | 0 | -6 | |
Adjusted EPS | 1 | 2 | 1 | 0 | -10 |
Particulars | 5 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | -1 | 2 | 7 | 5 | -1 | |
Cash Fr. Inv. | -6 | -7 | -22 | -17 | -6 | |
Cash Fr. Finan. | 10 | 2 | 18 | 9 | 6 | |
Net Change | 3 | -3 | 2 | -2 | 0 | |
Cash & Cash Eqvt | 3 | 0 | 3 | 0 | 0 |
Sun, 21 Apr 2024
Compliance Certificate Under Regulation 40(9) Compliance Certificate under Regulation 40(9) |
Sun, 21 Apr 2024
Reg. 34 (1) Annual Report. Annual Report for FY 2021-22 |
Sun, 21 Apr 2024
Compliance Certificate Under Regulation 7(3) Compliance Certificate under Regulation 7(3) |
Wed, 24 Apr 2024 |
Closing Below Previous Low |
Making Higher Highs for 2 Days |
High Decrease in 1 Month |
High Increase in 6 Months |
Bearish Engulfing |